147 related articles for article (PubMed ID: 10155050)
1. Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm.
Messina MS
Adv Ther; 1995; 12(3):157-63. PubMed ID: 10155050
[TBL] [Abstract][Full Text] [Related]
2. Outpatient management of asthma with regular nebulized beta agonists: comparison of bitolterol mesylate and isoproterenol.
Kemp JP; Orgel HA; Grossman J; Reed CE; Tinkelman DG; Webb DR; Ziment I
Ann Allergy; 1987 Jul; 59(1):17-20. PubMed ID: 3300436
[TBL] [Abstract][Full Text] [Related]
3. Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma.
Nathan RA; Bronsky EA; Dockhorn RJ; Kemp JP
Ann Allergy; 1994 Mar; 72(3):209-16. PubMed ID: 8129213
[TBL] [Abstract][Full Text] [Related]
4. Comparison of inhaled metaproterenol via metered-dose and hand-held nebulization in prehospital treatment of bronchospasm.
Rottman SJ; Robinson NE; Birnbaum ML
Prehosp Disaster Med; 1996; 11(4):280-4. PubMed ID: 10163609
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma.
Bierman CW; Kemp JP; Nathan RA
Ann Allergy Asthma Immunol; 1996 Jan; 76(1):27-35. PubMed ID: 8564625
[TBL] [Abstract][Full Text] [Related]
6. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
7. Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients.
Pinnas JL; Bhatt BD; Campbell SC; Kemp JP; Tinkelman DG
Chest; 1987 Apr; 91(4):533-9. PubMed ID: 3549173
[TBL] [Abstract][Full Text] [Related]
8. [Role of bronchospasm in impairment of bronchial permeability in bronchial asthma in attack-free period].
Nefedov VB; Popova LA
Klin Med (Mosk); 1999; 77(12):30-3. PubMed ID: 10684212
[TBL] [Abstract][Full Text] [Related]
9. Particle-size distribution of bitolterol mesylate solution delivered by four compressed-air nebulizer devices.
Hunke WA; Yu AB
Am J Hosp Pharm; 1987 Jun; 44(6):1392-6. PubMed ID: 3618619
[TBL] [Abstract][Full Text] [Related]
10. Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients.
Cuvelier A; Muir JF; Benhamou D; Weitzenblum E; Zuck P; Delacenserie R; Taytard A; Iacono P
Respir Care; 2002 Feb; 47(2):159-66. PubMed ID: 11812272
[TBL] [Abstract][Full Text] [Related]
11. [Role of bronchospasm in development of bronchial obstruction in chronic bronchitis].
Nefedov VB; Shergina EA
Ter Arkh; 2000; 72(11):57-9. PubMed ID: 11229314
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
[TBL] [Abstract][Full Text] [Related]
13. Equally efficacious asthma management with budesonide 800 micrograms administered by Turbuhaler or with beclomethasone dipropionate > or = 1500 micrograms given through a pressurized metered-dose inhaler with spacer. The French Budesonide Trial Group.
Piquet J; Zuck P; Dennewald G; Dugue P; Grivaux M; Brun P; Severac JC; Ostinelli J; Cheeseman KH
Adv Ther; 1996; 13(1):38-50. PubMed ID: 10172710
[TBL] [Abstract][Full Text] [Related]
14. The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm.
Sposato B; Mariotta S; Ricci A; Bruno P; Terzano C; Mannino F
Eur Rev Med Pharmacol Sci; 2005; 9(2):117-23. PubMed ID: 15945501
[TBL] [Abstract][Full Text] [Related]
15. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
Stoloff SW; Stempel DA; Meyer J; Stanford RH; Carranza Rosenzweig JR
J Allergy Clin Immunol; 2004 Feb; 113(2):245-51. PubMed ID: 14767437
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
17. Pyrbuterol: a new bronchodilator. Phase I-single dose study.
Steen SN; Ziment I; Thomas JS
Curr Ther Res Clin Exp; 1974 Oct; 16(10):1077-81. PubMed ID: 4215618
[No Abstract] [Full Text] [Related]
18. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy.
Tashkin DP; Klein GL; Colman SS; Zayed H; Schonfeld WH
Am J Med; 2007 May; 120(5):435-41. PubMed ID: 17466655
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma].
Yoshimi Y; Fujimura M; Yasui M; Kasahara K; Nakao S
Arerugi; 2004 May; 53(5):502-7. PubMed ID: 15247530
[TBL] [Abstract][Full Text] [Related]
20. [Results from comparative study of the bronchodilator effect of decloxizine in patients with reversible bronchospasm].
Hrouda J; Bogaard JM
Acta Tuberc Pneumol Belg; 1968; 59(4):742-8. PubMed ID: 5739760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
